EUVIMEDEUVIMED entdecken
Crossref

Toward Combating Pseudomonas aeruginosa Infection, the Creation of Azithromycin Derivatives Based on a Trojan Horse Strategy

Aoi Kimishima iD, Rina Suzuki, Taichi Kamo iD, Paul Wasuwanich iD, Hidehito Matsui, Sota Negami, Sota Honma, Yukiko Ujie, Naozumi Kondo iD, Hideaki Hanaki, Yukihiro Asami iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Aoi Kimishima und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Azithromycin, Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to Pseudomonas aeruginosa ( P. aeruginosa )’s inherent resistance to many antibiotics and the increasing incidence of multidrug‐resistant (MDR) organisms, P. aeruginosa infection has become a growing global threat to humanity. Azithromycin (AZM) does not have prominent antibacterial activity against P. aeruginosa at a clinically reasonable level because of the bacteria’s outer membrane and efflux pump system; however, it does demonstrate other properties, including reduction of inflammation and suppression of P. aeruginosa virulence. With the promising potential of AZM as an anti‐ P. aeruginosa active compound, we proposed the application of a Trojan horse strategy to the synthesis of AZM derivatives. In this study, we designed and synthesized catechol‐conjugated AZM derivatives and evaluated their anti‐ P. aeruginosa activity. One of the derivatives showed superior antibacterial activity to AZM, even against MDR P. aeruginosa clinical isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAzithromycinAnti-Bacterial AgentsPseudomonas InfectionsMicrobial Sensitivity TestsStructure-Activity RelationshipMolecular StructureHumansDose-Response Relationship, DrugCatechols

Stichwörter der Autor:innen

Pseudomonas aeruginosaantimicrobial resistanceazithromycincatecholgram‐negative bacteriamacrodiolide

Substanzen

AzithromycinAnti-Bacterial AgentsCatechols

Autor:innen und Institutionen

  • Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Tokyo, Japan.
  • Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, Tokyo, Japan.
  • Department of Internal Medicine, Mount Carmel Health System, Grove City, Ohio, USA.

ORCID-Profile: Aoi Kimishima, Taichi Kamo, Paul Wasuwanich, Naozumi Kondo, Yukihiro Asami

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Kimishima, A., Suzuki, R., Kamo, T., Wasuwanich, P., Matsui, H., Negami, S., Honma, S., Ujie, Y., Kondo, N., Hanaki, H., & Asami, Y. (2026). Toward Combating Pseudomonas aeruginosa Infection, the Creation of Azithromycin Derivatives Based on a Trojan Horse Strategy. ChemMedChem. https://doi.org/10.1002/cmdc.70498

Vancouver

Kimishima A, Suzuki R, Kamo T, Wasuwanich P, Matsui H, Negami S, et al. Toward Combating Pseudomonas aeruginosa Infection, the Creation of Azithromycin Derivatives Based on a Trojan Horse Strategy. ChemMedChem. 2026. doi:10.1002/cmdc.70498

BibTeX
@article{Kimishima2026,
  author = {Kimishima, Aoi and Suzuki, Rina and Kamo, Taichi and Wasuwanich, Paul and Matsui, Hidehito and Negami, Sota and Honma, Sota and Ujie, Yukiko and Kondo, Naozumi and Hanaki, Hideaki and Asami, Yukihiro},
  title = {Toward Combating Pseudomonas aeruginosa Infection, the Creation of Azithromycin Derivatives Based on a Trojan Horse Strategy},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70498}
}
Kostenlos starten →